PR Newswire PharmaOriginal article
Cell Stem Cell: tBE-mediated Base Editing Therapy Achieves Durable Clinical Remission in Sickle Cell Disease and β-Thalassemia Across Different Genetic Backgrounds
Data ReadoutpositivetBEPositive
AI Analysis
Summary
Cell Stem Cell published results demonstrating that tBE-mediated base editing therapy achieved durable clinical remission with 100% transfusion independence in sickle cell disease and β-thalassemia patients across Chinese, African, and South/Southeast Asian populations.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
tBE-mediated base editing therapy achieved durable clinical remission with 100% transfusion independence in Chinese TDT patients and confirmed equal safety and efficacy in African SCD patients and TDT patients from South/Southeast Asia
Importance:7/10
Sentiment:
0.85
gene therapybase editingsickle cell diseasethalassemiatransfusion independenceclinical data
Read the original article
Published by PR Newswire Pharma on September 8, 2026 12:00 AM